13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
33 檔
33.5%
According to the latest 13F quarterly dataset, Great Point Partners LLC managed an equity portfolio of $529.1M at the end of Q2 2024, spanning 33 distinct U.S. exchange-listed positions.
During Q2 2024, Great Point Partners LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | URGN | UroGen Pharma Ltd. | Stock-Other | 9.34% | — | +10.90% | |
| 2 | NGNE | Neurogene Inc | Stock-Other | 7.00% | -0.23% | — | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 6.26% | +15.22% | NEW | |
| 4 | ✓ | Merus N V | Stock-Other | 5.93% | — | +134.36% | |
| 5 | PLRX | Pliant Therapeutics Inc | Stock-Other | 5.43% | — | +42.39% | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 5.20% | — | +64.00% | |
| 7 | DVAX | Dynavax Technologies CORP | Stock-Other | 5.11% | — | +87.68% | |
| 8 | EOLS | Evolus Inc | Stock-Other | 5.10% | — | +0.07% | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.92% | — | +134.52% | |
| 10 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.76% | — | +21.27% | |
| 11 | INSM | Insmed Inc | Stock-Healthcare | 3.21% | — | -67.77% | |
| 12 | ✓ | Zura Bio LTD | Stock-Other | 3.11% | -1.07% | +68.33% | |
| 13 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.02% | -3.12% | EXIT | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.01% | — | — | |
| 15 | CNTX | Context Therapeutics Inc | Stock-Other | 2.85% | -1.35% | EXIT | |
| 16 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.84% | — | — | |
| 17 | ✓ | Optinose Inc | Stock-Other | 2.73% | — | +56.23% | |
| 18 | ESPR | Esperion Therapeutics Inc | Stock-Other | 2.46% | — | -27.61% | |
| 19 | VYGR | Voyager Therapeutics Inc | Stock-Other | 2.43% | — | — | |
| 20 | OTLK | Outlook Therapeutics Inc | Stock-Other | 2.41% | — | +14.97% | |
| 21 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.29% | — | +195.00% | |
| 22 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.75% | — | -1.36% | |
| 23 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.65% | — | — | |
| 24 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.50% | — | -12.26% | |
| 25 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.25% | — | -62.55% | |
| 26 | TCRX | Tscan Therapeutics Inc | Stock-Other | 1.05% | — | — | |
| 27 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 1.02% | — | -17.72% | |
| 28 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.98% | — | — | |
| 29 | PBYI | Puma Biotechnology Inc | Stock-Other | 0.93% | — | +10.64% | |
| 30 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.72% | — | +232.77% | |
| 31 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.61% | — | +7.69% | |
| 32 | ANAB | Anaptysbio Inc | Stock-Other | 0.12% | — | -97.44% | |
| 33 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 33 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including URGN, NGNE, ABVX) accounted for 33.5% of total reported equity market value during Q2 2024.
During Q2 2024, Great Point Partners LLC's top holdings by market value included URGN (9.3%)、NGNE (7.0%)、ABVX (6.3%). The largest single position, URGN, represented 9.3% of total portfolio value.
In Q2 2024, Great Point Partners LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.